ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
Dow Jones
38.686,32
1,51%
Euro vs US Dollar
1,08565
0,00%
Bitcoin
68.198,14
0,70%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Cognition Therapeutics Inc (CGTX)

  7. Cognition Therapeutics Inc (CGTX) News

CGTX

Cognition Therapeutics (CGTX)

Cognition Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:CGTX
DatumZeitQuelleÜberschriftSymbolFirma
07/05/202413h45Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CGTXCognition Therapeutics Inc
07/05/202413h39Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CGTXCognition Therapeutics Inc
11/03/202421h11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CGTXCognition Therapeutics Inc
11/03/202421h06Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CGTXCognition Therapeutics Inc
20/02/202422h44Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CGTXCognition Therapeutics Inc
20/02/202422h13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CGTXCognition Therapeutics Inc
20/02/202422h13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CGTXCognition Therapeutics Inc
10/02/202401h12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CGTXCognition Therapeutics Inc
19/01/202421h07Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:CGTXCognition Therapeutics Inc
09/01/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CGTXCognition Therapeutics Inc
08/01/202422h11Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:CGTXCognition Therapeutics Inc
04/01/202422h21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CGTXCognition Therapeutics Inc
04/01/202413h30GlobeNewswire Inc.Cognition Therapeutics CEO Issues Letter to ShareholdersNASDAQ:CGTXCognition Therapeutics Inc
29/12/202322h02Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:CGTXCognition Therapeutics Inc
16/11/202313h30GlobeNewswire Inc.Cognition Therapeutics Releases New Episode of “Conversations” Podcast Recorded at CTAD with Quantitative EEG Experts, Drs Willem de Haan and Philip ScheltensNASDAQ:CGTXCognition Therapeutics Inc
15/11/202313h30GlobeNewswire Inc.Cognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer’s and Parkinson’s DiseasesNASDAQ:CGTXCognition Therapeutics Inc
13/11/202323h25Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:CGTXCognition Therapeutics Inc
13/11/202323h17Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CGTXCognition Therapeutics Inc
13/11/202315h48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CGTXCognition Therapeutics Inc
13/11/202315h47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CGTXCognition Therapeutics Inc
07/11/202313h30GlobeNewswire Inc.Cognition Therapeutics Completes Enrollment in Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s DiseaseNASDAQ:CGTXCognition Therapeutics Inc
02/11/202312h45Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CGTXCognition Therapeutics Inc
02/11/202312h41Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CGTXCognition Therapeutics Inc
02/11/202312h30GlobeNewswire Inc.Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:CGTXCognition Therapeutics Inc
27/10/202313h30GlobeNewswire Inc.Cognition Therapeutics and Collaborators at Yale and ACTC Announce Oral Late-breaking Presentation on the START Study in Early Alzheimer’s Disease at CTADNASDAQ:CGTXCognition Therapeutics Inc
24/10/202322h30GlobeNewswire Inc.Cognition Therapeutics Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at CTADNASDAQ:CGTXCognition Therapeutics Inc
16/10/202313h30GlobeNewswire Inc.Cognition Therapeutics Presents New Data at CTAD Conference from Advancing Pipeline Across Multiple CNS IndicationsNASDAQ:CGTXCognition Therapeutics Inc
12/09/202313h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CGTXCognition Therapeutics Inc
07/09/202313h45GlobeNewswire Inc.Cognition Therapeutics Announces New Conversations Episode on Therapeutic Strategies to Protect the Retina in Dry AMDNASDAQ:CGTXCognition Therapeutics Inc
30/08/202314h00GlobeNewswire Inc.Cognition Therapeutics Announces Participation in Upcoming September ConferencesNASDAQ:CGTXCognition Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:CGTX

Kürzlich von Ihnen besucht

NYSE
XOM
Exxon Mobil
NYSE
JPM
JP Morgan Chase
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NASDAQ
NVDA
NVIDIA
CCOM
US30
US 30
TG
LHA
Deutsche Lufthansa
USOTC
DTEGY
Deutsche Telekom (QX)
CCOM
SILVER
SILVER
TG
NOV
Novo Nordisk
TG
BAYN
Bayer
TG
D7G
Nel ASA
NYSE
DIS
Walt Disney
TG
MBG
MercedesBenz
FX
EURJPY
Euro vs Yen
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten